Patent intelligence · EP
EP 3378477
NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN
NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN
Patent details — EP 3378477
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Sep 26, 2018
- Expiration
- Sep 21, 2038
- Applicant
- BIOPROJET PHARMA [FR]
- CPC classes
- A61K 31/ 4545 A I, A61K/314545, A61K/90053, A61P 3/ 00 A I
Quick answer
EP 3378477 (NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Sep 26, 2018. Expires Sep 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOPROJET PHARMA [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4545 A I, A61K/314545, A61K/90053, A61P 3/ 00 A I, A61P 3/ 10 A I, A61P 25/ 00 A I
More from BIOPROJET PHARMA [FR]
Related pharmaceutical patents in our USPTO index.
-
EP 4732903
COKRISTALLE VON PITOLISTANTHYDROCHLORID
granted -
EP 4681704
NEUE FORMULIERUNGEN VON PITOLISANT
granted -
US 2025120959
NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE
granted -
US 2024327366
POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE
granted -
EP 3906927
VERWENDUNG VON DOPAMIN-D3-TEILAGONISTEN ZUR BEHANDLUNG VON STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS
granted -
US 2020024256
TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
granted -
EP 2511275
Neuartige Piperidinyl-monocarboxylsäuren als S1P1 Rezeptoragonisten
granted
Frequently asked questions
What is US patent 3378477?
EP 3378477 (NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Sep 26, 2018. Expires Sep 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 3378477?
BIOPROJET PHARMA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does EP 3378477 expire?
Our index shows an expiration date of Sep 21, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.